Navigation Links
Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
Date:3/3/2010

RICHMOND, Calif., March 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic™ development programs and an overview of the company's business strategy at 11:00 am ET on Wednesday, March 10, 2010 at the Cowen and Company 30th Annual Health Care Conference which will be held in Boston.

A live webcast of the presentation will be available on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. A replay of the presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic™ development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.

SOURCE Sangamo BioSciences, Inc.

Back to top

RELATED LINKS
http://www.sangamo.com

'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
2. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
3. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
4. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
5. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
6. Sangamo Announces Pricing of Public Offering of Common Stock
7. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
8. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
9. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
10. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
11. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... evaluation of multiple immunoassay-based threat detection technologies by researchers from the Pacific ... biosensor threat detection technology was found to have the best level of ...
(Date:2/23/2017)... ... ... Today, researchers can fast-track sample collection and analysis for ... or SNPs of interest) using one, easy-to-collect saliva sample. With the addition of ... and other relevant biomarkers can be extensively studied through a non-invasive sample type. ...
(Date:2/23/2017)... , Feb. 23, 2017  Capricor Therapeutics, Inc. (NASDAQ: CAPR), ... medical conditions, today announced that Linda Marbán, Ph.D, president and ... investor conferences: Cowen and Company 37th ... am ET Boston, MA ... 9:00 am PT (12:00 pm ET) Dana Point, ...
(Date:2/23/2017)... FRANCISCO , Feb. 23, 2017   ViaCyte, ... Type 1, a not-for-profit advocacy and education group for ... grant from Beyond Type 1 to support ViaCyte,s efforts ... other insulin-requiring diabetes.  For more than ... cell replacement therapies with a focus on the treatment ...
Breaking Biology Technology:
(Date:2/3/2017)... 2017 A new independent identity strategy consultancy ... (IdSP) . Designed to fill a critical niche in ... founding partners Mark Crego and Janice ... in identity expertise that span federal governments, the 9/11 ... Crego-Kephart combined expertise has a common theme born from ...
(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
(Date:1/30/2017)... 2017   Invitae Corporation (NYSE: ... companies, today announced that it will report its fourth ... guidance on Monday, February 13, 2017, and Invitae,s management ... 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... review financial results, guidance, and recent developments and will ...
Breaking Biology News(10 mins):